Johnson & Johnson $JNJ Shares Acquired by Fifth Third Wealth Advisors LLC

Key Points

• Fifth Third Wealth Advisors LLC increased its holdings in Johnson & Johnson by 23.8% during the second quarter, acquiring a total of 32,942 shares valued at approximately $5 million.
• Johnson & Johnson reported $2.26 earnings per share and a revenue of $24.02 billion for the last quarter, with sell-side analysts projecting a fiscal year EPS of 10.58.
• The company declared a quarterly dividend of $1.30 per share, resulting in an annualized payout of $5.20 and a yield of 2.7%.

Fifth Third Wealth Advisors LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 23.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,942 shares of the company's stock after acquiring an additional 6,329 shares during the period. Fifth Third Wealth Advisors LLC's holdings in Johnson & Johnson were worth $5,032,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Horizon Bancorp Inc. IN raised its position in shares of Johnson & Johnson by 11.2% during the 2nd quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company's stock valued at $97,000 after acquiring an additional 64 shares in the last quarter. Global Strategic Investment Solutions LLC increased its position in Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock worth $294,000 after buying an additional 65 shares during the period. JSF Financial LLC increased its position in Johnson & Johnson by 2.2% in the second quarter. JSF Financial LLC now owns 2,993 shares of the company's stock worth $457,000 after buying an additional 65 shares during the period. Elios Financial Group Inc. increased its position in Johnson & Johnson by 1.5% in the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after buying an additional 66 shares during the period. Finally, Atlantic Family Wealth LLC increased its position in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after buying an additional 67 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.1%

Shares of JNJ stock opened at $190.88 on Tuesday. The stock has a 50-day simple moving average of $178.88 and a 200 day simple moving average of $163.97. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The stock has a market capitalization of $459.71 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $24.02 billion during the quarter. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on JNJ shares. Citigroup increased their target price on Johnson & Johnson from $200.00 to $213.00 and gave the stock a "buy" rating in a research report on Tuesday, October 7th. Barclays increased their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a "market perform" rating in a research report on Monday, October 6th. The Goldman Sachs Group raised their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a report on Thursday, October 9th. Finally, Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an "overweight" rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.